Physician profile
Michael I Zalkin
NPI 1831186626
$1,578.97
in general payments reported to CMS, 2019-2025
21 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $123 · 2021: $268 · 2022: $97.50 · 2023: $311 · 2024: $287 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $391.53 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $297.28 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Astellas Pharma US INC | $169.26 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $146.70 | 2021-2023 | Aptima |
| Mayne Pharma Commercial LLC | $89.40 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.03 | 2019-2025 | |
| Therapeuticsmd, INC. | $55.74 | 2019-2021 | |
| Tempus Ai, INC | $48.74 | 2025 | Xt Cdx |
| Exact Sciences Corporation | $46.14 | 2024-2025 | Cologuard Collection Kit |
| Vertical Pharmaceuticals, LLC | $40.17 | 2019 | |
| Sumitomo Pharma America, INC. | $34.63 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $27.32 | 2020-2021 | |
| Convatec INC. | $21.55 | 2023 | |
| Bard Access Systems, INC. | $18.66 | 2019 | |
| Coopersurgical, INC. | $17.96 | 2023 | Endosee |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $17.46 | 2024 | |
| Sage Therapeutics, LLC | $15.58 | 2025 | Zurzuvae |
| Millicent US INC | $15.33 | 2025 | Femlyv, Intrarosa |
| Daiichi Sankyo INC. | $14.42 | 2019 | |
| Agile Therapeutics, INC. | $13.35 | 2021 | |
| Exeltis, USA INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zalkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.